



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/47	A1	(11) International Publication Number: WO 98/39003 (43) International Publication Date: 11 September 1998 (11.09.98)											
<p>(21) International Application Number: PCT/GB98/00675</p> <p>(22) International Filing Date: 6 March 1998 (06.03.98)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>9704809.4</td> <td>7 March 1997 (07.03.97)</td> <td>GB</td> </tr> <tr> <td>9722232.7</td> <td>21 October 1997 (21.10.97)</td> <td>GB</td> </tr> <tr> <td>9724263.0</td> <td>17 November 1997 (17.11.97)</td> <td>GB</td> </tr> <tr> <td>9724712.6</td> <td>21 November 1997 (21.11.97)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): CEREBRUS LIMITED [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB).</p> <p>(71) Applicant (for US only): SHEPHERD, Joy, Miriam (heiress of the deceased inventor) [GB/GB]; 37 Duke Street, Windsor, Berkshire SL4 1SH (GB).</p> <p>(72) Inventor: SHEPHERD, Robin (deceased).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): FLETCHER, Allan [GB/GB]; 216B Windsor Road, Burnham, Buckinghamshire SL1 7HN (GB).</p>	9704809.4	7 March 1997 (07.03.97)	GB	9722232.7	21 October 1997 (21.10.97)	GB	9724263.0	17 November 1997 (17.11.97)	GB	9724712.6	21 November 1997 (21.11.97)	GB	<p>(74) Agent: HOWARD, Paul, Nicholas; Carpmals & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
9704809.4	7 March 1997 (07.03.97)	GB											
9722232.7	21 October 1997 (21.10.97)	GB											
9724263.0	17 November 1997 (17.11.97)	GB											
9724712.6	21 November 1997 (21.11.97)	GB											
(54) Title: USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA													
<p>(57) Abstract</p> <p>Use of (+)-(11R,2'S)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (-)-enantiomer in the manufacture of a medicament having reduced side-effect compared to the racemic (\pm)-(R*,S*)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol for treating or preventing malaria in a subject. A method of treating or preventing malaria with reduced side-effects comprising administration of (+)-(11R,2'S)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (-)-enantiomer.</p>													

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA

The present invention relates to the use of an enantiomer of α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol (mefloquine) as an anti-malarial.

Malaria is an infectious parasitic disease transmitted by mosquitoes. It is characterized by periodic fever and an enlarged spleen. Malaria affects some 200 million people a year. Malaria in humans is caused by 4 species of parasitic protozoa belonging to the genus *Plasmodium*. Of these, *P. falciparum* produces the severe disease while *P. malariae*, *P. vivax* and *P. ovale* cause milder forms.

Malaria is transmitted by infected female *Anopheline* mosquitoes. The *Plasmodia* parasite matures in the insect, and is then transferred when the mosquito bites a human. Inside the human, the parasite settles first in the liver, multiplies and then invades the red blood cells. This is when the symptoms of malaria become evident.

Despite numerous attempts at eradication, malaria remains a serious endemic disease in many areas of Africa, Latin America and Oceania, with a worldwide mortality rate of approximately 1 million per year (WHO Scientific Group on the Chemotherapy of Malaria 1990). One of the major factors contributing to the continued presence of malaria is the emergence of malaria parasites that are resistant to one or more anti-malarial compounds.

30

Mefloquine is an anti-malarial compound which is effective against strains of the *Plasmodium* parasite which have developed resistance to conventional anti-malarial agents (for a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy, see Palmer et al, Drugs, 1993, 45, 430-475). However, mefloquine resistance has now been reported in a number of areas including areas

of Thailand (see Palmer et al.). Nevertheless, mefloquine is still one of the most effective anti-malarial monotherapies and its use has increased greatly. Recently, the drug has attracted considerable adverse publicity owing to the incidence of severe neuropsychiatric side-effects, e.g. depression, psychosis, panic attacks, generalised anxiety.

Although central nervous system (CNS) side-effects had been reported previously (particularly from its use by the armed forces in tropical areas; Croft & World
10 (Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet, 1996, 347, 326); Gullahorn et al. (Anaesthesia emergence delirium after mefloquine prophylaxis. Lancet, 1993, 341, 632)), their incidence had been regarded as sufficiently low to be of little concern.
15 However, the widespread use of the drug by holidaymakers has resulted in a greatly increased number of CNS side-effect reports. A recent study (Barrett et al. (Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial
20 prophylaxis: postal and telephone survey of travellers. (British Medical Journal, 1996, 313, 525-528), in which 3851 travellers taking prophylactic anti-malarial medication were surveyed, has confirmed that there is a significant excess of adverse neuropsychiatric events
25 associated with mefloquine administration compared with an alternative prophylactic treatment (proguanil plus chloroquine).

Clinical reports indicate that mefloquine may be
30 proconvulsant (Ruff et al. (Seizure associated with mefloquine for malaria prophylaxis. Med. J. Aust., 1994, 161, 453)), anxiogenic (Hennequin et al. (Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch. Intern. Med., 1994, 154,
35 2360-2362)), induce vertigo and dizziness (Sowunmi et al. (Neuropsychiatric side effects of mefloquine in Africans.

3

Trans. Roy. Soc. Trop. Med. Hyg., 1993, 87, 462-463)) and may have central anticholinergic actions (Speich and Heller (Central anticholinergic syndrome with the antimalarial drug mefloquine. N. Engl. J. Med., 1994, 331, 57-58)).


5

Mefloquine is a molecule having two asymmetric carbon atoms and is usually used clinically as a racemic mixture of erythro ((±)(R*,S*)) isomers. Both of the mefloquine enantiomers have been reported to be equally effective
10 against *Plasmodium falciparum* (Basco et al. (In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against *Plasmodium falciparum*. Br. J. clin. Pharmac., 1992, 33, 517-520)), although another study claimed that the (+)-enantiomer was more potent than the
15 (-)-enantiomer by a factor of 1.69-1.81 (Karle et al. (*Plasmodium falciparum*: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp. Parasitol., 1993, 76, 345-351)).


20 Mefloquine hydrochloride was introduced to the market as an anti-malarial agent in 1985. There have been over 40 families of patent applications on mefloquine covering: the use of the compound for treating malaria and other parasitic diseases; various processes for its preparation;
25 and different formulations. The compound and its preparation was first described by Ohnmacht et al. (J. Med. Chem. 1971, 14, 926) in 1971. A more detailed account of the stereochemistry, synthesis, and anti-malarial activity of the isomers of mefloquine is given by Carroll and
30 Blackwell (J. Med. Chem. 1974, 17, 210-219) in 1974.

It has now been found that the (+)-(11R,2'S)-enantiomer of α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol is effective as an anti-malarial and has
35 reduced side-effects compared to the racemic (+)-(R*,S*)-α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol.

The structures of the (+)-(11R,2'S)-enantiomer and the (-)-(11S,2'R)-enantiomer of α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol are shown below.



(+)-enantiomer
(+)-(11R, 2'S)



(-)-enantiomer
(-)-(11S, 2'R)

5

In particular, it has been found that the (-)-enantiomer of mefloquine binds to CNS adenosine receptors, while the (+)-enantiomer is without significant activity at this binding site. The blocking of central adenosine receptors by the
10 (-)-enantiomer is believed to result in the neuropsychiatric symptoms associated with mefloquine.

According to the present invention there is provided use of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-
15 quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (-)-enantiomer in the manufacture of a medicament having reduced side-effects compared to the racemic (+)-(R*,S*)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol for treating or
20 preventing malaria.

According to a further aspect of the present invention there is provided a method of treating or preventing malaria with reduced side-effects compared to the racemic
25 (+)-(R*,S*)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-

5

quinolinemethanol comprising administration to a subject in need of such treatment an effective dose of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-

4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (-)-enantiomer.

The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.

10

(+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-

4-quinolinemethanol may be employed in the present invention in an admixture with one or more other anti-malarial drugs such as, for example, chloroquine, pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine, halofantrine, artemether/artesunate, tovaquone, proguanil, doxycycline and dapsone. Combination with pyrimethamine and sulfadoxine is particularly preferred. According to a further aspect of the invention, (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol and the other anti-malarial drug(s) may be in separate formulations, for use simultaneously or sequentially.

The term "a method for treating or preventing malaria" as used herein, means relief from malaria, preventing or inhibiting infection by parasitic protozoa of the genus *Plasmodium* which cause malaria and clearance of parasitic protozoa.

The term "substantially free of its (-)-enantiomer", as used herein, means that the composition contains a greater proportion of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol in relation to (-)-(11S,2'R)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-

4-quinolinemethanol. In a preferred embodiment of the present invention the term "substantially free of its (-)-enantiomer" as used herein means that the composition

contains at least 90% by weight of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol and 10% by weight or less of (-)-(11S,2'R)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol. In a further preferred embodiment, the term "substantially free of its (-)-enantiomer" means that the composition contains at least 99% by weight of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol and 1% or less of (-)-(11S,2'R)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol. In another preferred embodiment, the term "substantially free of its (-)-enantiomer" as used herein means that the composition contains 100% by weight of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol. The above percentages are based on the total amount of α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol present in the composition.

The term "reduced side-effects", as used herein, means that the pharmaceutical compositions employed in the present invention allow treatment and prevention of malaria and cause less side-effects than the racemic (+)-(R*,S*)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol.

In a preferred embodiment of the present invention the term "reduced side effects", as used herein, means that the pharmaceutical compositions employed in the present invention allow treatment and prevention of malaria and cause substantially less side-effects than the racemic (+)-(R*,S*)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-

quinolinemethanol. In a more preferred embodiment of the present invention the term "reduced side-effects", as used herein, means that the pharmaceutical composition employed in the present invention allow treatment and prevention of malaria and cause substantially no side-effects. The side-effects that are reduced, preferably substantially reduced, and more preferably avoided, include neuropsychiatric side-effects such as depression, psychosis, irritability,

7

aggressiveness, panic attacks and generalised anxiety; seizures; proconvulsant effects; agitation effects; vertigo; dizziness; and anticholinergic symptoms.

Preferably, the pharmaceutical compositions employed in the present invention exhibit reduced, preferably substantially reduced, preferably eliminated side effects associated with purinergic receptor binding activity.

It has been found that the (-)-enantiomer binds strongly to the adenosine receptor, while the (+)-enantiomer exhibits only a weak binding interaction.

There is evidence that blockade of adenosine receptors can result in a number of neuropsychiatric symptoms including tremor, anxiety, panic, insomnia and convulsions.

Adenosine receptors represent a sub-class (P_1) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. The main pharmacologically distinct adenosine receptor subtypes are known as A_1 , A_{2A} , A_{2B} (of high and low affinity) and A_3 . Recent studies on mice bred without the adenosine A_{2A} receptor (Ledent et al., (Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A_{2A} receptor. Nature, 1997, 388, 674-678)) indicate that these animals are more aggressive and anxious as well as having higher blood pressure than normal mice.

The effects in humans and laboratory animals of the adenosine receptor antagonists of theophylline, an asthma drug, and caffeine are well documented. These two drugs have fairly weak in vitro affinities at adenosine receptors (K_i values: theophylline A_1 8.5 μ M, A_{2A} , 25 μ M; caffeine A_1 29 μ M, A_{2A} , 48 μ M) (Jacobson, K.A. and van Rhee, A.M. (Development of Selective Purinoceptor Agonists and Antagonists, in Purinergic Approaches in Experimental Therapeutics, K.A. Jacobson and M. Jarvis (Eds)., John

Wiley and Sons, Inc., New York, 1997., pp 101-128)).

Patients taking theophylline are warned that they should inform their physicians if they have a seizure disorder, 5 which is not surprising in view of the seizure inducing potential of adenosine receptor antagonists. Overdose with xanthines can result in seizures that are particularly refractory to treatment with clinically useful anticonvulsants (Chu, C.K. (Caffeine and aminophylline 10 induced seizures. *Epilepsia* 1981, 22, 85-94)).

Adenosine is thought to be the agent that causes seizure arrest in man (Knutsen, L.J.S. and Murray, T. Adenosine and ATP in Epilepsy. In "Purinergic Approaches in Experimental 15 Therapeutics", K.A. Jacobson and M. Jarvis (Eds)., John Wiley and Sons, Inc., New York, 1997, pp 423-447), and experimental data from rodents indicates that blockade of adenosine A₁ receptors by theophylline immediately prior to an ischaemic episode exacerbates neuronal damage (Rudolphi, 20 K.A.; Keil, M.; Hinze, H.J. Effect of theophylline on ischemically induced hippocampal damage in Mongolian Gerbils:, a behavioral and histopathological study. *J. Cereb. Blood Flow Metab.* 1987, 7,74-81).

Given the undesired CNS effects observed in mammals with 25 the relatively weak adenosine receptor antagonists theophylline and caffeine documented in the scientific literature, it is undesirable to administer to normal human subjects a potent adenosine receptor antagonist.

According to the present invention the use of the (+)- 30 enantiomer of mefloquine, substantially free of the (-)-enantiomer, is particularly preferred in the treatment of a subject who has consumed or is likely to consume any chemical compound which interacts with a purinergic receptor. Consumption of such a compound includes 35 ingestion of such a compound in food or drink, and

9

administration of a drug, for example for treatment or prophylaxis of a medical condition by any route of administration (such as, but not limited to, oral ingestion). Compounds which interact with purinergic
5 receptors particularly include compounds which interact with adenosine receptors. Such compounds include caffeine, theobromine, theophylline, carbamazepine, papaverine and dipyridamole; particularly caffeine, theobromine, theophylline, carbamazepine and papaverine; more
10 particularly, caffeine, theobromine, theophylline and carbamazepine; more particularly caffeine, theobromine and theophylline; more particularly caffeine and theobromine; most particularly caffeine. Compounds which interact with purinergic receptors also include ethanol.

15

According to a further aspect of the present invention, the use of the (+)-enantiomer of mefloquine, substantially free of the (-)-enantiomer, is particularly preferred in the treatment of a subject having, or at risk from, a medical
20 condition related to a disorder of purinergic receptor function. Medical conditions related to purinergic receptor activity include conditions causing or caused by an imbalance in purinergic receptor activity and conditions for which the medication causes an imbalance in purinergic
25 receptor activity. Such medical conditions include, for example, neuropsychiatric disorders, cardiovascular disorders, digestive disorders, bronchial disorders and erectile dysfunction. Neuropsychiatric disorders of the CNS include psychiatric disorders [such as depression and
30 anxiety disorders (such as panic disorders)], sleep disorders and seizure disorders. Cardiovascular disorders, which may be diagnosed or undiagnosed, include ischaemic heart disease, arrhythmia and related disorders, congestive heart failure and cerebrovascular disease (including
35 transient ischaemic attacks). Subjects having cardiovascular disorders (or cardiovascular system investigations) particularly include subjects undergoing

10

treatment with a beta-blocker drug, vasodilator or nifedipine. Subjects having digestive disorders particularly include subjects undergoing treatment with proton pump inhibitors. Bronchial disorders particularly include asthma and chronic obstructive pulmonary disease. Subjects having bronchial disorders particularly include subjects undergoing treatment with theophylline.

The pharmaceutical compositions employed in the present invention comprise (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol as an active ingredient or a pharmaceutically acceptable salt thereof and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients known to those skilled in the art, such as one or more other anti-malarial drugs such as, for example, chloroquine, pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine, halofantrine, artemether/artesunate, tovaquone, proguanil, doxycycline and dapson. The term, "pharmaceutically acceptable salts", refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids.

Since the compound employed in the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most particularly preferred is the hydrochloride salt.

Any suitable route of administration may be employed for

11

providing the patient with an effective dosage of (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol. For example, oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, 5 and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like. The most suitable route in any given case will depend on the severity of the condition being treated. The most preferred route of 10 administration of the present invention is the oral route.

The compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

15 In practical use, (+)-(11R,2'S)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may 20 take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed as carriers, such as, 25 for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, 30 granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations. The most preferred solid 35 oral preparation is tablets.

Because of their ease of administration, tablets and

12

capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.

5

In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in United States Patent Nos.: 3,845,770;
10 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719;
4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.

Pharmaceutical compositions employed in the present
15 invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water
20 emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general,
25 the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

30

For example, a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in
35 a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Moulded tablets may

13

be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The invention is further defined by reference to the following Figures and examples. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practised without departing from the purpose and interest of this invention.

Figure 1 shows binding of the mefloquine (+)- and (-)-enantiomers to bovine striatal adenosine receptors (non-selective) (displacement of [³H]-NECA ([³H]-5'-N-ethylcarboxamidoadenosine)). Table 2 displays comparative data for the control compound MECA (5'-N-methylcarboxamidoadenosine).

Figure 2 shows binding of the mefloquine (+)- and (-)-enantiomers to rat brain adenosine A₁ receptors (displacement of [³H]-DPCPX, an adenosine A₁ receptor antagonist).

Figure 3 shows binding of the mefloquine (+)- and (-)-enantiomers to human recombinant (HEK-293) adenosine A_{2A} receptors (displacement of [³H]-CGS 21680, an adenosine A_{2A} receptor agonist).

Figure 4 shows binding of the mefloquine (+)- and (-)-enantiomers to human recombinant (HEK-293) adenosine A₃ receptors (displacement of [¹²⁵I]AB-MECA, an adenosine A₃ receptor agonist).

Figure 5 shows the effect of the mefloquine (+)- and (-)-enantiomers on the NECA-induced increase in extracellular acidification rate (ECAR) in PC-12 cells.

Figure 6 shows the effect of the mefloquine (+)- and (-)-enantiomers on the CGS 21680-induced increase in ECAR in PC-12 cells.

EXAMPLES**Preparation of 2,8-bis(trifluoromethyl)quinoline-4-carboxylic acid.**

5 The compound 2,8-bis(trifluoromethyl)quinoline-4-carboxylic acid was prepared by the method of Hickmann et al (United States Patent 4,327,215).

Preparation of N-Methoxy-N-methyl-2,8-bis(trifluoromethyl)-quinoline-4-carboxamide.

10 This compound was prepared using synthetic methodology reported by Thiesen et al (J. Org. Chem. 1988, 53, 2374). To a suspension of 2,8-bis(trifluoromethyl)quinoline-4-carboxylic acid (12.5 g, 40.4 mmol) in CH₂Cl₂ (200 ml) was added 1,1'-carbonyldiimidazole (7.3 g, 45 mmol) and N,O-
15 dimethylhydroxylamine hydrochloride (4.25 g, 45 mmol). The resulting deep red solution was stirred overnight, then poured into dilute hydrochloric acid (0.25 M, 200 ml). The organic phase was separated, and washed in turn with dilute sodium hydroxide and brine, and dried (MgSO₄). The
20 solvents was evaporated to leave a viscous brown oil, which was filtered through a pad of silica gel using ethyl acetate-hexane (1:1) as eluent to give a yellowish oil, 14.3 g (98 %), which solidified on standing. This material was broken up under hexane to afford the product as a tan
25 solid, m.p. 93-95 °C. δ_H (400MHz, CDCl₃) 8.22 (1H, d, J=1.5 Hz), 8.16 (1H, d, J=1.8 Hz), 7.85 (1H, s), 7.73 (1H, t, J=1.2 Hz), 3.52 (3H, b s) and 3.41 (3H, bs). Analysis of this material by HPLC showed it to be >99.8% pure.

Preparation of Pyridin-2-yl-2,8-bis(trifluoromethyl)-4-quinolinemethanone.

To a solution of the amide described above (10 g, 28.4 mmol) in anhydrous ether (100 ml) was added a solution of

15

2-pyridyl lithium (Pinder et al (*J. Med. Chem.* 1968, **11**, 267)) [formed by addition of 2-bromopyridine (3.3 ml, 34.6 mmol) to a solution of butyl lithium (29.7 ml of a commercial 1.6 M solution, diluted with an equal quantity 5 of ether) at -78°C] at -78°C. Analysis of the reaction by TLC after 10 min showed that no starting material remained.

The reaction was allowed to warm to room temperature, then poured into aqueous ammonium acetate, and extracted with ether (2 x 100 ml), the combined organic layers washed with 10 brine and dried (MgSO₄). Filtration through a pad of silica gel using ethyl acetate-hexane (1:1) afforded 9.0 g (84%) of the crude product. This was recrystallised from isopropyl alcohol to give the product as colourless needles, identical to that described in the literature 15 (Hickmann et al; Pinder et al; Ohnmacht et al; and Adam et al. (*Tetrahedron* 1991, **36**, 7609)).

Preparation of (R*,S*)-(±)-α-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol (Mefloquine).

This compound was prepared according to the literature 20 procedure (Hickmann et al; Pinder et al; and Ohnmacht et al) to give an 85:15 mix of the erythro:threo isomers (HPLC). Recrystallisation of the crude material from acetonitrile afforded the erythro isomer as a powdery white solid in >98% purity (HPLC).

25

Resolution of erythro enantiomers was performed according to the known procedure (Carroll, F.I. and Blackwell, J.T., *J. Med. Chem.*, 1974, **17**, 210-219).

30 Measurement of Convulsant or Proconvulsant Effects

Several animal seizure models are available for the screening and characterisation of convulsant, proconvulsant and anticonvulsant drugs. Most models employ a chemical 35 convulsant to induce seizures and the convulsant effects of

16

novel compounds are measured in terms of their ability to change the dose of convulsant required to induce a seizure response (or to alter the latency to seizure onset following a bolus dose of the convulsant). Most chemical convulsants work by blocking the neurotransmitter function of gamma-aminobutyric acid (GABA), the predominant inhibitory neurotransmitter in the mammalian brain. This can be achieved by blocking the postsynaptic action of GABA using pentylenetetrazol or bicuculline, or via a presynaptic action using a GABA synthesis inhibitor such as 3-mercaptopropionic acid, an inhibitor of glutamate decarboxylase (GAD) to decrease GABA release into the synapse.

15 Potentiation of Pentylenetetrazole-Induced Seizures to Assess Pro-Convulsant Effects Produced by a Test Compound in Mice.

Seizure thresholds were determined in unrestrained animals following the insertion of an infusion cannula into a lateral tail vein. The infusion cannulas comprised lengths of polythene tubing (Portex 800/100/100/100 for mice fitted with hypodermic needles removed from their plastic Luer holders (Gillette 25G or 23G respectively)).

25 Once inserted into the tail vein these cannulas did not require any additional attachment. The incidence of cannulas becoming dislodged during the seizures was extremely low (approximately 2% of the trials). An infusion pump was used to deliver the convulsant drug (Pentylenetetrazole, 12 mg/ml) dissolved in isotonic saline at a constant rate 0.15 ml/min (mice). The animals were placed in a transparent Perspex enclosure for observation and the times to onset of clonic and tonic seizures were measured. The criteria used to define these events were: 35 myoclonus accompanied by abrupt loss of righting reflex (clonic) and rigid extension of the fore-limbs (tonic).

17

**Measurement of Overt Physiological and Behavioral Effects
in Mice using the Irwin Screen.**

Animals were weighed, coded and placed in cages, and then allowed to habituate to the environment for 20 minutes.

5 Five animals were allocated per treatment group. Body temperature was recorded (rectally in the mouse) prior to drug administration. The compound was administered at various doses, including a vehicle control group. Treatment groups were coded so that the operator was
10 unaware of drug or dose given.

Animals were placed in Perspex chambers for observations at 20, 60, 180 minutes after injection for a period of 10-15 minutes. If the compound was administered intravenously, animals were placed into Perspex chambers immediately after
15 injection for observation. Body temperature and any behavioral changes were recorded.

Pilot studies were carried out initially to determine doses of compound to be used in an experiment. Only 3 animals were used per dose group. An initial low dose was
20 administered and subsequent doses given were higher or lower depending on effects produced. Time of onset of drug action and maximum effects were also recorded.

Observations made were categorised in qualitative terms. A checklist of the behavioral and physiological signs used to
25 assess overt effects of test compounds is shown in Table 1.

Table 1. Check-List of Observations for Irwin Screening

	OVERT BEHAVIOUR	AUTONOMIC OBSERVATIONS
	increased activity	piloerection
5	decreased activity	diarrhoea
	sedation	exophthalmos
	tremor	salivation
	convulsions	vasoconstriction
	-myoclonic	vasodilatation
10	-tonic/clonic	cyanosis
	straub tail	lacrymation
	stereotypy	ptosis
	increased exploration	miosis
	decreased exploration	mydriasis
15	ataxia	
	weakness	hypothermia
	catalepsy	
	pain threshold (tail pinch)	
	loss of righting reflex	
20	writhing (i.p. administration)	

Biological Results

The behavioral effects of the two enantiomers of mefloquine were assessed following daily dosing (30,100,300 mg/kg p.o) in mice using an Irwin Screen. Clear qualitative differences were observed between the two enantiomers, with the (-)-enantiomer appearing more potent in eliciting spontaneous seizures, irritability and aggressiveness. Twenty-four hours after the first dose, animals given 300 mg/kg of the (-)-enantiomer were difficult to handle and displayed aggression toward cage-mates. After 48 hr, the same group of animals displayed spontaneous clonic seizures, increased reactivity, and reduced body weight. Within five days, the high dose (-)-enantiomer treated

19

animals showed reduced activity, unkempt appearance and assumed a hunched body posture. Although the latter effects were observed in animals treated with the (+)-enantiomer, these effects only became apparent after 5-6 5 days, and did not include seizures.

In a subsequent study to assess the possibility of a pro-convulsant effect of the (-)-enantiomer, it was found that 24 hrs after a single injection of either the (+)- or (-)- 10 enantiomer (30, 100, 300 mg/kg p.o), a dose of 300 mg/kg of the (-)-enantiomer significantly reduced the latency to onset of clonic seizures induced by infusion of the convulsant drug pentylenetetrazole (PTZ). These 15 observations are consistent with the reported neuropsychiatric side-effects of mefloquine in humans, and indicate that the (+)-enantiomer of mefloquine has significantly reduced side-effects.

Adenosine Receptor Interaction

20

The mefloquine (+)- and (-)-enantiomers were initially examined separately in an assay measuring in vitro binding to adenosine receptors by determining the displacement of [³H]-NECA binding to bovine striatal membranes. The data 25 are shown in Figure 1 and Table 2.

20

Table 2. Binding of the mefloquine (+)- and (-)-enantiomers to bovine striatal adenosine receptors (displacement of [3 H]-NECA). MECA is shown as control.

K _i	
MECA	58 nM
(+)-enantiomer	38 μ M
(-)-enantiomer	83 nM

5

Once it was established that the (-)-enantiomer of mefloquine exhibited displacement of [3 H]-NECA in bovine striatum, the adenosine receptor subtype binding was examined using radioligand binding assays employing the selective P₁ radioligands [3 H]-DPCPX (adenosine A₁ receptor), [3 H]-CGS 21680 (adenosine A_{2A} receptor) and [125 I]AB-MECA (adenosine A₃ receptor). The results are summarised in Table 3, with comparative literature data for 15 other adenosine receptor ligands. The full dose response curves are shown in Figures 2-4.

Table 3. Binding of mefloquine (+)- and (-)- enantiomers to adenosine A₁, A_{2A} and A₃ receptors

BINDING ASSAY CONDITIONS			
	Adenosine A ₁	Adenosine A _{2A}	Adenosine A ₃
Source	Rat Brain	Human	Human
Ligand	0.14 nM [³ H]-DPCPX	4.0 nM [³ H]-CGS 21680	0.4 nM [¹²⁵ I]AB-MECA
Non-Specific	10 µM PIA	10 µM NECA	10 µM NECA
RESULTS (K _i)			
(+) enantiomer	6.4 µM	1.8 µM	7.7 µM
(-) enantiomer	202 nM	4.4 nM	6.8 µM
Reference Adenosine receptor agonists			
NECA	17 nM	19 nM	110 nM
CHA	26 nM	510 nM	7700 nM
Reference Adenosine A _{2A} receptor antagonists			
KW-6002†	580 nM	13 nM	na
KF17837†	390 nM	8 nM	na
ZM241385‡	2.0 µM	0.3 nM	151 µM

5

† Shimada et al., *BioMed. Chem. Lett.*, **1997**, 7, 2349-2352.

* Poucher et al., *Br. J. Pharm.*, **1995**, 115: 1096-1102

The above data lead to the conclusion that the mefloquine (-)-enantiomer is a selective ligand for the adenosine A_{2A} 10 receptor subtype in vitro. The binding of the (+)-enantiomer is over two orders of magnitude weaker.

Assessment of the interaction of the (+)-enantiomer and the (-)-enantiomer with NECA in PC-12 cells

PC-12 cells (purchased from ECACC) were maintained in RPMI 15 1640 media (Sigma) supplemented with 2mM L-glutamine and 10% FCS in a controlled environment of 5% CO₂, 95% humidity at 37°C.

22

On the day of the assay the cells were gently harvested and centrifuged at 700 RPM for 10 min. The supernatant was discarded and the pellet re-suspended to a final density of approx. 1×10^6 cells/ml in modified RPMI 1640 media. 600 μ l of this suspension was mixed with 200 μ l of molten agarose cell entrapment media (Molecular Devices) pre-incubated to 37°C. The cell suspension was returned to the incubator for a further 10 minutes for equilibration. 10 μ l of this cell agarose suspension was spotted onto the middle of the capsule insert well and allowed to set before being placed in the sensor chambers in the cytosensor® microphysiometer. The cells were maintained on the instrument with the low buffering capacity modified RPMI 1640 media (Molecular Devices) and their base line extracellular acidification rates allowed to settle.

Agonist concentration curves were constructed by exposing the cells to increasing concentrations of agonist for a total exposure time of approximately 1 min 53 sec. Agonist concentration curves in the presence of antagonists were performed following pre-incubation of the cells to the antagonists for at least 20 min prior to agonist exposure (in the presence of the fixed antagonist concentration). Baseline acidification rates were normalised to 100%, and all responses were calculated as a % increase over normalised baseline.

All data was fitted to Log-concentration response curves to calculate half maximally effective concentrations (EC_{50} values) by non-linear regression using the Graph Pad Prism software package.

The results (shown in Figure 5) indicate that the (-)-enantiomer, (-)-(11S,2'R)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol, binds to adenosine receptors as an antagonist. PC12 cells endogenously express adenosine A_{2A} receptors and have been

23

used as a source of functionally-coupled A_{2A} receptors. Figure 6 shows that similar results are obtained when CGS 21680, a selective A_{2A} receptor agonist, is used instead of NECA. The antagonist effect of the (-)-enantiomer is 5 specific to adenosine A_{2A} receptors.

CLAIMS

1. Use of (+)-(11R,2'S)- α -2-piperidinyl-2,8-
5 bis(trifluoromethyl)-4-quinolinemethanol or a
pharmaceutically acceptable salt thereof substantially free
of its (-)-enantiomer in the manufacture of a medicament
having reduced side-effects compared to the racemic (+)-
(R*,S*)- α -2-piperidinyl-2,8-bis(trifluoromethyl)-4-
10 quinolinemethanol for treating or preventing malaria in a
subject.
2. A method of treating or preventing malaria with
reduced side-effects compared to the racemic (+)-(R*,S*)- α -
15 2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
comprising administration to a subject in need of such
treatment an effective dose of (+)-(11R,2'S)- α -2-
piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or
a pharmaceutically acceptable salt thereof substantially
20 free of its (-)-enantiomer.
3. A use or method according to claim 1 or 2 wherein the
subject is human.
- 25 4. A use or method according to any one of claims 1 to 3
wherein (+)-(11R,2'S)- α -2-piperidinyl-2,8-
bis(trifluoromethyl)-4-quinolinemethanol is in an admixture
with one or more other anti-malarial drugs.
- 30 5. A use or method according to claim 4 wherein said
anti-malarial drugs are selected from chloroquine,
pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine,
halofantrine, artemether/artesunate, tovaquone, proguanil,
doxycycline and dapsone.
- 35 6. A use or method according to any one of claims 1 to 5
wherein the subject has consumed or is likely to consume a

chemical compound which ²⁵ interacts with purinergic receptors.

7. A use or method according to claim 6 wherein the 5 subjects has ingested or is likely to ingest caffeine, theobromine, theophylline, carbamazepine, papaverine or dipyridamole.

8. A use or method according to claim 6 wherein the 10 subject has ingested or is likely to ingest ethanol.

9. A use or method according to any one of claims 1 to 5 wherein the subject has, or is at risk from, a medical condition related to a disorder of purinergic receptor 15 function.

10. A use or method according to claim 9 wherein the medical condition is a neuropsychiatric disorder.

20 11. A use or method according to claim 10 wherein the medical condition is depression.

12. A use or method according to claim 10 wherein the medical condition is an anxiety disorder.

25

13. A use or method according to claim 12 wherein the medical condition is a panic disorder.

14. A use or method according to claim 10 wherein the 30 medical condition is a sleep disorder.

15. A use or method according to claim 9 wherein the medical condition is a seizure disorder.

35 16. A use or method according to claim 9 wherein the medical condition is a cardiovascular disorder.

26

17. A use or method according to claim 16 wherein the medical condition is a diagnosed cardiovascular disorder.

18. A use or method according to claim 16 wherein the medical condition is ischaemic heart disease.

19. A use or method according to claim 16 wherein the medical condition is congestive heart failure.

20. A use or method according to claim 16 wherein the medical condition is cerebrovascular disease.

21. A use or method according to claim 20 wherein the medical condition is transient ischaemic attacks.

15

22. A use or method according to claim 17 wherein the subject is undergoing treatment with beta-blocker drugs.

23. A use or method according to claim 17 wherein the subject is undergoing treatment with a vasodilator.

24. A use or method according to claim 17 wherein the medical condition is arrhythmia or a related disorder.

25. A use or method according to claim 17 wherein the subject is undergoing treatment with nifedipine.

26. A use or method according to claim 9 wherein the medical condition is a digestive disorder.

30



27. A use or method according to claim 26 wherein the subject is undergoing treatment with a proton pump inhibitor.

28. A use or method according to claim 9 wherein the medical condition is a bronchial disorder.



27

29. A use or method according to claim 28 wherein the medical condition is asthma.
30. A use or method according to claim 29 wherein the subject is undergoing treatment with theophylline.
31. A use or method according to claim 28 wherein the medical condition is chronic obstructive pulmonary disease.
- 10 32. A use or method according to claim 9 wherein the medical condition is erectile dysfunction.



1/3

FIG. 1**FIG. 2**

2/3

FIG. 3**FIG. 4**

3/3

FIG. 5**FIG. 6**

- CGS21680
○ CGS+1 μM (-) enantiomer
● CGS+1 μM (+) enantiomer

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00675

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	W. PETERS ET AL.: "The chemotherapy of rodent malaria. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomers." ANN. TROP. MED. PARASITOL., vol. 89, no. 5, 1995, pages 465-468, XP002067842 see the whole document	1, 2
A	J.M. KARLE ET AL.: "Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents." EXP. PARASITOL., vol. 176, no. 4, 1993, pages 345-351, XP002067843 cited in the application	

-/--

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 June 1998

Date of mailing of the international search report

24/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	<p>S. VIDREQUIN ET AL.: "Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes" DRUG METAB. DISPOS., vol. 24, no. 6, 1996, pages 689-691, XP002067844 -----</p>	